In an attempt to identify relevant biomarkers of response to ICI we analyzed a cohort of patients with metastatic melanoma undergoing ICI therapy and we characterized low-density CD15+ PMNs by their ability to inhibit T cell proliferation or directly kill T cells and by their maturity phenotype. This evidence concerns the gene FUT4 and metastatic melanoma.